GeneDx (WGS) Competitors $119.83 -2.28 (-1.87%) As of 02:29 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock WGS vs. HIMS, GH, RDNT, BTSG, SHC, OPCH, PRVA, HTFL, VCYT, and CONShould you be buying GeneDx stock or one of its competitors? The main competitors of GeneDx include Hims & Hers Health (HIMS), Guardant Health (GH), RadNet (RDNT), BrightSpring Health Services (BTSG), Sotera Health (SHC), Option Care Health (OPCH), Privia Health Group (PRVA), Heartflow (HTFL), Veracyte (VCYT), and Concentra Group Holdings Parent (CON). These companies are all part of the "healthcare" industry. GeneDx vs. Its Competitors Hims & Hers Health Guardant Health RadNet BrightSpring Health Services Sotera Health Option Care Health Privia Health Group Heartflow Veracyte Concentra Group Holdings Parent Hims & Hers Health (NYSE:HIMS) and GeneDx (NASDAQ:WGS) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, media sentiment, profitability, risk, institutional ownership and analyst recommendations. Which has preferable valuation and earnings, HIMS or WGS? Hims & Hers Health has higher revenue and earnings than GeneDx. Hims & Hers Health is trading at a lower price-to-earnings ratio than GeneDx, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHims & Hers Health$1.48B9.03$126.04M$0.8073.76GeneDx$362.32M9.52-$52.29M$0.052,401.50 Do insiders & institutionals hold more shares of HIMS or WGS? 63.5% of Hims & Hers Health shares are owned by institutional investors. Comparatively, 61.7% of GeneDx shares are owned by institutional investors. 17.7% of Hims & Hers Health shares are owned by company insiders. Comparatively, 29.6% of GeneDx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Do analysts prefer HIMS or WGS? Hims & Hers Health presently has a consensus price target of $38.92, suggesting a potential downside of 34.05%. GeneDx has a consensus price target of $104.13, suggesting a potential downside of 13.28%. Given GeneDx's stronger consensus rating and higher possible upside, analysts plainly believe GeneDx is more favorable than Hims & Hers Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hims & Hers Health 3 Sell rating(s) 9 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 1.93GeneDx 1 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is HIMS or WGS more profitable? Hims & Hers Health has a net margin of 9.63% compared to GeneDx's net margin of 0.39%. Hims & Hers Health's return on equity of 26.26% beat GeneDx's return on equity.Company Net Margins Return on Equity Return on Assets Hims & Hers Health9.63% 26.26% 13.06% GeneDx 0.39%16.51%9.35% Does the media prefer HIMS or WGS? In the previous week, Hims & Hers Health had 17 more articles in the media than GeneDx. MarketBeat recorded 30 mentions for Hims & Hers Health and 13 mentions for GeneDx. GeneDx's average media sentiment score of 0.87 beat Hims & Hers Health's score of 0.66 indicating that GeneDx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hims & Hers Health 13 Very Positive mention(s) 6 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GeneDx 3 Very Positive mention(s) 5 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, HIMS or WGS? Hims & Hers Health has a beta of 2.25, indicating that its share price is 125% more volatile than the S&P 500. Comparatively, GeneDx has a beta of 1.98, indicating that its share price is 98% more volatile than the S&P 500. SummaryHims & Hers Health beats GeneDx on 9 of the 16 factors compared between the two stocks. Get GeneDx News Delivered to You Automatically Sign up to receive the latest news and ratings for WGS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding WGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart WGS vs. The Competition Export to ExcelMetricGeneDxMedical Services IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.45B$8.23B$6.03B$10.49BDividend YieldN/A2.17%5.73%4.80%P/E Ratio2,401.5072.9284.8927.32Price / Sales9.5233.67516.27196.49Price / Cash118.1222.0937.5761.53Price / Book13.726.9412.396.78Net Income-$52.29M$247.60M$3.32B$276.59M7 Day Performance-2.13%-1.55%0.22%-0.21%1 Month Performance-1.61%0.55%9.87%7.65%1 Year Performance100.16%10.15%75.52%33.95% GeneDx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)WGSGeneDx2.4372 of 5 stars$120.08-1.7%$104.13-13.3%+104.4%$3.45B$362.32M2,401.501,200News CoverageHIMSHims & Hers Health3.3321 of 5 stars$58.12+0.3%$38.92-33.0%+164.1%$13.10B$1.48B72.651,637Trending NewsAnalyst ForecastInsider TradeGap UpGHGuardant Health3.5577 of 5 stars$65.32+3.0%$65.86+0.8%+193.2%$7.91B$739.02M-19.502,021RDNTRadNet2.9752 of 5 stars$76.08-2.3%$76.80+0.9%+4.5%$5.99B$1.91B-380.3811,021Positive NewsBTSGBrightSpring Health Services2.6674 of 5 stars$28.89+1.7%$29.88+3.4%+95.7%$5.03B$12.57B93.2035,000News CoverageAnalyst ForecastGap UpSHCSotera Health2.7912 of 5 stars$16.00-0.5%$17.20+7.5%+3.8%$4.57B$1.10B200.033,000News CoverageOPCHOption Care Health4.8563 of 5 stars$27.19+0.3%$35.11+29.1%-11.4%$4.40B$5.00B21.758,088Positive NewsPRVAPrivia Health Group3.5448 of 5 stars$24.53+2.2%$28.58+16.5%+39.7%$2.95B$1.74B223.021,140HTFLHeartflowN/A$35.76+2.2%$36.60+2.3%N/A$2.92B$148.54M0.00699Positive NewsVCYTVeracyte3.5862 of 5 stars$35.10+1.4%$40.90+16.5%+0.1%$2.72B$445.76M106.37790CONConcentra Group Holdings Parent3.1134 of 5 stars$20.87-0.4%$27.75+33.0%-3.4%$2.69B$1.90B17.5411,250 Related Companies and Tools Related Companies HIMS Competitors GH Competitors RDNT Competitors BTSG Competitors SHC Competitors OPCH Competitors PRVA Competitors HTFL Competitors VCYT Competitors CON Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:WGS) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GeneDx Holdings Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share GeneDx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
